Close Menu

Calimmune

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

NEW YORK (GenomeWeb) – CalImmune this week announced that it has been cleared by the US Food and Drug Administration to treat a second cohort of patients in a clinical trial of its expressed RNAi-based treatment for HIV infection.

Calimmune has become the latest RNAi drug developer to move into the clinic, recently initiating a phase I/II trial of its HIV therapy Cal-1.

Two years after the US Patent and Trademark Office reinstated its core patent, Australia's Benitec Biopharma has once again set its sights on finding licensees for its expressed RNAi intellectual property.

Title: Triggered RNAi
Patent Number: 8,241,854
Filed: May 22, 2009
Lead Inventor: Peng Yin, California Institute of Technology

Benitec Biopharma said this week that it has non-exclusively licensed its expressed RNAi technology to Calimmune for use in developing an RNAi-based HIV/AIDS treatment.

Nature News reports on the US National Science Foundation's investigations of undisclosed foreign ties among researchers it funds.

Researchers have developed a set of 10 principles to guide how a list of all species on earth should be put together, the Guardian reports.

Wired reports on a new firm developing a gene writing approach for therapeutic genome changes.

In Nature this week: a method called cis-X combines whole-genome and transcriptome sequencing data to identify regulatory noncoding variants, and more.